NovaBay Historical Balance Sheet

NBY Stock

USD 0.69 0.01 1.47%

Trend analysis of NovaBay Pharmaceuticals balance sheet accounts such as Common Stock Shares Outstanding of 125.5 K provides information on NovaBay Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of NovaBay Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using NovaBay Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining NovaBay Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether NovaBay Pharmaceuticals is a good buy for the upcoming year.

NovaBay Pharmaceuticals Inventory

3.47 Million

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.

About NovaBay Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of NovaBay Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. NovaBay Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of NovaBay Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which NovaBay currently owns. An asset can also be divided into two categories, current and non-current.

NovaBay Pharmaceuticals Balance Sheet Chart

At this time, NovaBay Pharmaceuticals' Current Deferred Revenue is fairly stable compared to the past year. Short and Long Term Debt Total is likely to rise to about 3.3 M in 2025, whereas Other Assets are likely to drop slightly above 461.6 K in 2025.

Total Assets Other Assets Common Stock Shares Outstanding Other Stockholder Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of NovaBay Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in NovaBay Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Most accounts from NovaBay Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into NovaBay Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.At this time, NovaBay Pharmaceuticals' Current Deferred Revenue is fairly stable compared to the past year. Short and Long Term Debt Total is likely to rise to about 3.3 M in 2025, whereas Other Assets are likely to drop slightly above 461.6 K in 2025.

	2022	2023	2024	2025 (projected)
Total Liabilities	5.8M	5.7M	6.6M	7.1M
Other Stockholder Equity	165.1M	176.1M	202.5M	212.6M

Total Liab Other Stockholder Equity

NovaBay Pharmaceuticals balance sheet Correlations

	Total Assets	Total Stockholder Equity	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Other Current Assets	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment	Other Liab	Current Deferred Revenue	Non Current Liabilities Total	Short Long Term Debt Total	Short Term Debt
Total Assets		0.83	-0.36	-0.18	0.26	0.45	0.07	0.14	0.26	-0.61	-0.21	-0.17	0.68	0.63	0.63	0.48	0.6	0.29	0.86	0.6	0.22	0.2	-0.09	0.12	-0.17	0.0
Total Stockholder Equity	0.83		-0.11	-0.33	0.05	-0.11	-0.07	-0.23	0.2	-0.76	0.0	-0.41	0.77	0.34	0.75	0.5	0.52	0.16	0.88	0.63	0.24	0.15	0.08	-0.17	-0.31	-0.19
Other Assets	-0.36	-0.11		0.08	0.05	-0.48	-0.39	-0.43	-0.2	0.25	-0.09	-0.55	-0.29	-0.01	-0.38	-0.32	-0.4	-0.11	-0.39	-0.3	-0.16	0.37	0.54	0.07	-0.06	-0.44
Common Stock Shares Outstanding	-0.18	-0.33	0.08		0.18	0.22	0.07	0.59	-0.07	0.28	-0.26	-0.32	-0.22	-0.17	-0.29	-0.33	-0.53	-0.14	-0.15	-0.29	-0.39	-0.39	0.35	-0.14	0.83	0.08
Other Stockholder Equity	0.26	0.05	0.05	0.18		0.29	0.26	0.61	0.47	0.41	-0.96	0.09	-0.26	0.39	-0.41	0.36	0.22	0.7	-0.08	0.01	0.57	0.7	-0.12	-0.34	0.36	0.15
Total Liab	0.45	-0.11	-0.48	0.22	0.29		0.23	0.61	0.11	0.06	-0.33	0.36	0.04	0.6	-0.03	0.05	0.22	0.16	0.15	0.11	-0.07	0.03	-0.28	0.54	0.16	0.25
Other Current Liab	0.07	-0.07	-0.39	0.07	0.26	0.23		0.54	-0.07	-0.16	-0.23	0.34	0.21	-0.34	0.14	0.04	0.09	-0.07	0.2	-0.26	0.06	-0.07	-0.38	-0.36	0.26	0.12
Total Current Liabilities	0.14	-0.23	-0.43	0.59	0.61	0.61	0.54		0.38	0.3	-0.64	0.28	-0.14	0.09	-0.24	0.12	-0.03	0.35	0.0	-0.04	0.17	0.0	-0.21	-0.24	0.69	0.38
Property Plant And Equipment Net	0.26	0.2	-0.2	-0.07	0.47	0.11	-0.07	0.38		0.24	-0.44	0.02	-0.03	0.26	0.02	0.5	0.09	0.89	0.1	0.27	0.78	0.5	-0.21	-0.26	0.12	0.55
Net Debt	-0.61	-0.76	0.25	0.28	0.41	0.06	-0.16	0.3	0.24		-0.42	0.25	-0.96	0.01	-0.93	-0.27	-0.41	0.4	-0.87	-0.52	0.29	0.32	0.11	-0.02	0.38	0.16
Retained Earnings	-0.21	0.0	-0.09	-0.26	-0.96	-0.33	-0.23	-0.64	-0.44	-0.42		-0.11	0.27	-0.43	0.45	-0.33	-0.18	-0.61	0.12	-0.05	-0.47	-0.63	0.09	0.28	-0.35	-0.09
Accounts Payable	-0.17	-0.41	-0.55	-0.32	0.09	0.36	0.34	0.28	0.02	0.25	-0.11		-0.25	0.05	-0.26	0.21	0.41	0.07	-0.31	0.1	0.14	0.01	-0.66	0.1	-0.19	0.25
Cash	0.68	0.77	-0.29	-0.22	-0.26	0.04	0.21	-0.14	-0.03	-0.96	0.27	-0.25		0.04	0.95	0.37	0.38	-0.22	0.9	0.55	-0.2	-0.2	-0.25	-0.01	-0.33	0.07
Non Current Assets Total	0.63	0.34	-0.01	-0.17	0.39	0.6	-0.34	0.09	0.26	0.01	-0.43	0.05	0.04		-0.03	0.34	0.48	0.39	0.2	0.45	0.21	0.48	0.02	0.55	-0.28	-0.11
Cash And Short Term Investments	0.63	0.75	-0.38	-0.29	-0.41	-0.03	0.14	-0.24	0.02	-0.93	0.45	-0.26	0.95	-0.03		0.31	0.32	-0.2	0.89	0.47	-0.12	-0.28	-0.22	0.0	-0.36	0.11
Common Stock Total Equity	0.48	0.5	-0.32	-0.33	0.36	0.05	0.04	0.12	0.5	-0.27	-0.33	0.21	0.37	0.34	0.31		0.77	0.46	0.35	0.69	0.45	0.36	-0.5	-0.26	-0.26	0.34
Other Current Assets	0.6	0.52	-0.4	-0.53	0.22	0.22	0.09	-0.03	0.09	-0.41	-0.18	0.41	0.38	0.48	0.32	0.77		0.18	0.43	0.73	0.27	0.24	-0.41	-0.01	-0.46	-0.04
Property Plant And Equipment Gross	0.29	0.16	-0.11	-0.14	0.7	0.16	-0.07	0.35	0.89	0.4	-0.61	0.07	-0.22	0.39	-0.2	0.46	0.18		-0.02	0.14	0.9	0.74	-0.17	-0.22	0.14	0.44
Total Current Assets	0.86	0.88	-0.39	-0.15	-0.08	0.15	0.2	0.0	0.1	-0.87	0.12	-0.31	0.9	0.2	0.89	0.35	0.43	-0.02		0.53	0.03	-0.13	-0.06	-0.07	-0.15	-0.03
Common Stock	0.6	0.63	-0.3	-0.29	0.01	0.11	-0.26	-0.04	0.27	-0.52	-0.05	0.1	0.55	0.45	0.47	0.69	0.73	0.14	0.53		0.08	0.04	-0.24	-0.01	-0.42	0.07
Property Plant Equipment	0.22	0.24	-0.16	-0.39	0.57	-0.07	0.06	0.17	0.78	0.29	-0.47	0.14	-0.2	0.21	-0.12	0.45	0.27	0.9	0.03	0.08		0.67	-0.13	-0.38	0.02	0.23
Other Liab	0.2	0.15	0.37	-0.39	0.7	0.03	-0.07	0.0	0.5	0.32	-0.63	0.01	-0.2	0.48	-0.28	0.36	0.24	0.74	-0.13	0.04	0.67		-0.15	-0.03	-0.22	0.11
Current Deferred Revenue	-0.09	0.08	0.54	0.35	-0.12	-0.28	-0.38	-0.21	-0.21	0.11	0.09	-0.66	-0.25	0.02	-0.22	-0.5	-0.41	-0.17	-0.06	-0.24	-0.13	-0.15		0.02	0.35	-0.71
Non Current Liabilities Total	0.12	-0.17	0.07	-0.14	-0.34	0.54	-0.36	-0.24	-0.26	-0.02	0.28	0.1	-0.01	0.55	0.0	-0.26	-0.01	-0.22	-0.07	-0.01	-0.38	-0.03	0.02		-0.37	-0.09
Short Long Term Debt Total	-0.17	-0.31	-0.06	0.83	0.36	0.16	0.26	0.69	0.12	0.38	-0.35	-0.19	-0.33	-0.28	-0.36	-0.26	-0.46	0.14	-0.15	-0.42	0.02	-0.22	0.35	-0.37		0.07
Short Term Debt	0.0	-0.19	-0.44	0.08	0.15	0.25	0.12	0.38	0.55	0.16	-0.09	0.25	0.07	-0.11	0.11	0.34	-0.04	0.44	-0.03	0.07	0.23	0.11	-0.71	-0.09	0.07

Click cells to compare fundamentals

NovaBay Pharmaceuticals Account Relationship Matchups

NovaBay Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	15.2M	24.0M	16.4M	9.0M	10.4M	14.4M
Total Stockholder Equity	12.3M	10.2M	10.6M	3.3M	3.0M	5.3M
Other Assets	477K	912K	476K	489K	562.4K	461.6K
Common Stock Shares Outstanding	28.6K	35.6K	46K	120.4K	138.5K	125.5K
Liabilities And Stockholders Equity	15.2M	24.0M	16.4M	9.0M	10.4M	14.4M
Other Stockholder Equity	148.0M	150.9M	165.1M	176.1M	202.5M	212.6M
Total Liab	2.9M	13.8M	5.8M	5.7M	6.6M	7.1M
Other Current Liab	1.7M	763K	667K	1.5M	1.7M	1.3M
Total Current Liabilities	2.8M	3.4M	4.3M	4.3M	4.9M	4.1M
Property Plant And Equipment Net	520K	604K	2.0M	1.4M	1.6M	1.0M
Net Debt	(11.4M)	(7.0M)	(3.3M)	(390K)	(448.5K)	(470.9K)
Retained Earnings	(136.1M)	(141.9M)	(158.2M)	(174.8M)	(157.4M)	(149.5M)
Accounts Payable	302K	1.0M	1.1M	1.1M	1.3M	812.7K
Cash	12.0M	7.5M	5.4M	3.1M	2.8M	2.7M
Non Current Assets Total	996K	10.8M	5.1M	1.9M	2.2M	2.0M
Cash And Short Term Investments	12.0M	7.5M	5.4M	3.1M	2.8M	2.7M
Other Current Assets	576K	778K	560K	388K	446.2K	463.4K
Property Plant And Equipment Gross	520K	1.2M	2.6M	2.1M	2.4M	2.5M
Total Current Assets	14.2M	13.2M	11.3M	7.2M	6.4M	9.5M
Common Stock	418K	478K	652K	112K	128.8K	122.4K
Property Plant Equipment	110K	520K	604K	2.0M	1.8M	1.8M
Current Deferred Revenue	730K	1.3M	1.8M	946K	851.4K	1.2M
Non Current Liabilities Total	87K	10.4M	1.6M	1.4M	1.3M	1.2M
Short Long Term Debt Total	503K	551K	2.0M	2.7M	3.2M	3.3M
Short Term Debt	832K	505K	906K	1.6M	1.9M	2.0M
Net Receivables	1.1M	1.7M	2.0M	759K	872.9K	1.7M
Net Tangible Assets	5.0M	973K	12.3M	(237K)	(213.3K)	(202.6K)
Capital Surpluse	125.7M	148.0M	150.9M	165.1M	189.8M	118.8M
Inventory	608K	3.2M	3.4M	2.9M	3.3M	3.5M
Non Current Liabilities Other	198K	4.6M	561K	334K	300.6K	285.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

Additional Tools for NovaBay Stock Analysis

When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NovaBay Historical Balance Sheet

NovaBay Pharmaceuticals Inventory

3.47 Million

About NovaBay Balance Sheet Analysis

NovaBay Pharmaceuticals Balance Sheet Chart

Total Assets

Common Stock Shares Outstanding

NovaBay Pharmaceuticals balance sheet Correlations

NovaBay Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

NovaBay Pharmaceuticals balance sheet Accounts

Also Currently Popular

Additional Tools for NovaBay Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 0.95	Cash
Total Current Assets	+ 0.9	Cash
Property Plant Equipment	+ 0.9	Property Plant And Equipment Gross
Property Plant And Equipment Gross	+ 0.89	Property Plant And Equipment Net
Total Current Assets	+ 0.89	Cash And Short Term Investments
Total Current Assets	+ 0.88	Total Stockholder Equity

Cash	- 0.96	Net Debt
Retained Earnings	- 0.96	Other Stockholder Equity
Cash And Short Term Investments	- 0.93	Net Debt
Total Current Assets	- 0.87	Net Debt
Net Debt	- 0.76	Total Stockholder Equity
Short Term Debt	- 0.71	Current Deferred Revenue